Residence at 1200 m Induces a Threefold Reduction in the Risk of Acute Mountain Sickness After Rapid Ascent to 3600 m

Résumé fourni par la source

Moderate-altitude residence (1600-2400 m) elicits altitude acclimatization and reduces acute mountain sickness (AMS) after rapid ascent to higher altitude (HA). Cross-sectional studies suggest lower-altitude residence (800-1200 m) provides similar benefits, but conclusions are unclear due to a lack of control. PURPOSE: Determine whether moderate-altitude residents (MAR, 1200 m) experience less AMS than low-altitude residents (LAR) after active or passive ascent to HA (3600 m). METHODS: Seventy-eight soldiers (mean ± standard deviation; age = 26 ± 5 yr; women = 8) were tested at their baseline residence at 331 m (LAR; n = 41) or 1200 m (MAR; n = 37), transported to Taos, NM (2845 m), hiked ( n = 39) or were driven ( n = 39) to 3600 m and stayed for 4 d. AMS was assessed using the Environmental Symptoms Questionnaire twice on day 1 (HA1), five times on days 2 and 3 (HA2, HA3), and once on day 4 (HA4). Daily peak cerebral factor score (AMS-C) was recorded; if AMS-C was ≥0.7, individuals were considered sick that day. RESULTS: Ascent condition (active vs passive) did not demonstrate a significant main or interaction effect on AMS. The MAR versus LAR experienced lower AMS incidence on HA1 (16% vs 44%, P = 0.008) and HA2 (19% vs 39%, P = 0.05), similar incidence on HA3 (14% vs 29%, P = 0.08), and lower incidence on HA4 (0% vs. 17%, P = 0.007). AMS-C was lower in MAR versus LAR on HA1 (0.40 ± 0.49 vs 0.74 ± 0.86, P = 0.04), HA2 (0.30 ± 0.34 vs 0.86 ± 0.88, P = 0.001), HA3 (0.30 ± 0.36 vs 0.56 ± 0.69, P = 0.03), and HA4 (0.09 ± 0.14 vs 0.35 ± 0.58, P = 0.01). MAR exhibited an approximately threefold reduction in the odds of developing AMS at HA1 (odds ratio [OR] = 0.25, P = 0.01), HA2 (OR = 0.37, P = 0.05), and HA3 (OR = 0.38, P = 0.09) compared with LAR. CONCLUSIONS: Residence at 1200 m induces a threefold reduction in the odds of developing AMS after rapid ascent to 3600 m.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.